Close Menu

NEW YORK – Qiagen said after the close of the market on Thursday that it has acquired the remaining approximately 80 percent of diagnostics developer NeuMoDx Molecular that it did not already own for $248 million in cash.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.